SANGAMO THERAPEUTICS, INC true Amendment 1 0001001233 0001001233 2020-06-18 2020-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2020

SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 000-30171 |  | 68-0359556
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer ID Number)

7000 Marina Blvd., Brisbane, California 94005

(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.01 par value per share |  | SGMO |  | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note:

This amended Current Report on Form 8-K is being filed solely for the purposes of amending and restating Item 9.01 in order to furnish a revised Exhibit 99.2, which contained an error in the version originally furnished. Other than updating Item 9.01 to correct Exhibit 99.2, there are no other changes to the Form 8-K as originally filed.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. |  |  | Description
| 99.1 |  |  | Press release dated June 18, 2020 (incorporated by reference to the initial filing)
| 99.2 |  |  | World Federation of Hemophilia Virtual Summit Data Presentation
| 104 |  |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  | SANGAMO THERAPEUTICS, INC.
Dated: June 18, 2020 |  | By: |  | /s/ Gary H. Loeb
|  | Name: |  | Gary H. Loeb
|  | Title: |  | Executive Vice President and General Counsel